BioSpace News Archive

Recently, the iPSC therapeutics leading global platform company - Help Therapeutics announced the completion of Series C financing of 25 millions of dollars.

A small but significant percentage of college athletes with COVID-19 develop myocarditis, a potentially dangerous inflammation of the heart muscle, that can only be seen on cardiac MRI, according to a study being presented at the annual meeting of the Radiological Society of North America.

WorldIPI.com has signed an agreement with D.K. Zabolotny Institute of Microbiology and Virology of the National Academy of Science of Ukraine to clinically test a new protective mask that may offer significant benefit in the fight against all airborne viruses and bacterial particles, including Covid-19.

Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, announced its COVID-19 diagnostic strategy in response to the emergence of Omicron, a newly identified SARS-CoV-2 variant of concern.

Financing will accelerate HotSpot’s transition into a clinical development company while enabling expansion of its product pipeline.

Digital Health Pioneer to Focus on External Innovation; Becomes Co-Chair of BD Scientific Advisory Board.

Anavex Life Sciences Corp. today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021 at 12:10 p.m. ET.

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announces the appointment of Susan McClatchey as Vice President, Head of Quality.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that the United States Federal Food and Drug Agency (“FDA”) has approved a protocol amendment to its Tigris trial allowing for the use of sequential organ failure assessment (“SOFA”) scoring as inclusion criteria into the study.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that data from its rare disease programs will be delivered in three presentations at the American Epilepsy Society 2021 Annual Meeting.